NorthStar and BIOEMTECH Partner to Supply Actinium-225 for Preclinical Research

NorthStar Medical Radioisotopes of Beloit, Wis. agreed to supply Actinium-225 (Ac-225) to Athens-based BIOEMTECH to secure reliable isotope access for preclinical radiopharmaceutical research. The strategic supply pact is intended to remove a bottleneck in early targeted alpha therapeutic development and to support studies run on BIOEMTECH’s high-resolution PET and SPECT imaging platforms.

The companies announced the agreement on February 17, 2026, positioning the supply line as a way to “strengthen access to Ac-225 for the preclinical research community.” “We are pleased to partner with NorthStar Isotopes to strengthen access to Ac‑225 for the preclinical research community,” said Dr. Maritina Rouchota, Chief Quality Officer of BIOEMTECH. “Reliable isotope supply is a major bottleneck in early radiopharmaceutical development. This agreement enables our customers to run more predictable, higher‑impact studies using our imaging platforms.” ContractPharma prints the CQO surname as Rouchata, PhD, a spelling discrepancy noted in company and trade coverage.

Frank Scholz, President and CEO of NorthStar Medical Radioisotopes, framed the deal around capacity expansion for the market. “NorthStar is committed to expanding Ac‑225 supply for the growing radiopharmaceutical market,” Scholz said. “Working with BIOEMTECH to support preclinical researchers aligns with our mission to advance global access to radiopharmaceuticals with dependable isotope supply with the required quality and regulatory standards.”

Operational details in trade reporting indicate this is not purely a headline partnership but an active supply channel. ContractPharma reports that initial deliveries of Ac-225 are expected to commence by the end of the first quarter of 2026 and that BIOEMTECH customers will be able to request supply through BIOEMTECH’s ordering channels. ContractPharma also states NorthStar will provide isotope-specific documentation and guidance on handling to support compliant shipments and translational workflows.

BIOEMTECH is described in the announcement as a developer of preclinical and translational imaging systems and is identified elsewhere as a contract research organization; NorthStar is identified as a commercial-stage radiopharmaceutical company based in Beloit, Wis. Both companies emphasized compliance and logistics: BIOEMTECH’s announcement said the arrangement “ensures the quality, compliance and logistics required for translational development,” language reiterated in BIOEMTECH’s LinkedIn post on February 17.

Notably absent from the company statements were contract financials, volumes, and term length. The supplied materials do not include specific activity-per-vial, shipment frequency, isotopic purity specifications, or exclusivity terms. Additional background included in trade reporting: NorthStar adjusted its leadership in late 2025, with Victor Miller serving as Chief Financial Officer and Kathy Spencer-Pike named Chief Commercial Officer effective December 1, 2025.

If deliveries begin by the timeline reported, BIOEMTECH’s customers could see steadier access to Ac-225 for preclinical studies within weeks. For now, the announcement fixes two concrete facts for the field: NorthStar and BIOEMTECH signed a supply agreement on February 17, 2026, and the partnership is explicitly aimed at addressing the Ac-225 bottleneck in early radiopharmaceutical development.